CN113637738B - SNP locus related to coronary heart disease and application thereof - Google Patents
SNP locus related to coronary heart disease and application thereof Download PDFInfo
- Publication number
- CN113637738B CN113637738B CN202110905130.XA CN202110905130A CN113637738B CN 113637738 B CN113637738 B CN 113637738B CN 202110905130 A CN202110905130 A CN 202110905130A CN 113637738 B CN113637738 B CN 113637738B
- Authority
- CN
- China
- Prior art keywords
- heart disease
- coronary heart
- gene
- locus
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention belongs to the field of biotechnology research, and discloses SNP loci related to coronary heart disease and application thereof. In particular to the application of IL5 gene rs2069812 locus or IL5 gene rs2057687 locus in preparing coronary heart disease examination and screening medicaments, wherein the coronary heart disease comprises myocardial infarction and angina pectoris; application of detection reagent of IL5 gene rs2069812 locus and/or IL5 gene rs2057687 locus in preparing coronary heart disease detection screening medicine; the application of the allelic type obviously related to the susceptibility of the coronary heart disease in preparing the coronary heart disease examination and screening medicine; the application of the low-risk alleles of coronary heart disease in preparing coronary heart disease examination and screening medicines. The invention discovers a new coronary heart disease detection site, discovers different risk grades aiming at different alleles, and provides a new scheme for diagnosing and preventing the subsequent coronary heart disease and the like.
Description
Technical Field
The invention belongs to the field of biotechnology research, and particularly relates to SNP loci related to coronary heart disease and application thereof.
Background
Coronary heart disease (Coronary artery disease, CAD) is a complex cardiovascular disease (Cardiovascular disease, CVD) caused by both genetic and environmental factors, the pathological basis of which is coronary Atherosclerosis (AS) or (and) coronary artery spasm, when the coronary artery develops Atherosclerosis, which can cause stenosis or blockage of the coronary lumen leading to insufficient blood supply to the heart, and is also called ischemic heart disease (Ischemic heart disease, IHD). CAD is one of the ten killers that jeopardize human health and is one of the leading causes of population death worldwide. The WHO statistics of the 2016 world health organization show that mortality caused by IHD is the leading cause of great economic and medical burden to society and reduced quality of life for people worldwide. The chinese cardiovascular disease report in 2017 showed that chinese CVD prevalence is in a continuously rising phase from 1995 to 2015. The number of CVD patients in China is up to 2.9 hundred million at present, and the number of CAD patients reaches 1100 ten thousand.
The third generation genetic marker is a Single Nucleotide Polymorphism (SNP), which often refers to a single base change on a DNA sequence in the genome. SNPs are distributed throughout the human genome, one SNP per 1000 nucleotides in the human genome, and more than 300 kilo-base SNPs are shared in 30 hundred megabases in humans. SNPs are the most common and effective genetic markers currently being studied for disease. In recent years, the prediction of occurrence and development of diseases by utilizing SNP has become a hotspot of clinical and scientific researchers, and the application value in the prediction of serious diseases such as tumor, cardiovascular and cerebrovascular diseases and the like has become the forefront.
Although a large number of coronary heart disease susceptibility genes have been found through genetic studies, these susceptibility genes can only explain about 28% of the heritability of coronary heart disease, whereas it has been found through family aggregation studies and twin studies that coronary heart disease heritability is as high as 40% or more, so that a considerable part of the genetic basis of coronary heart disease is not clarified, and further studies on the genetic basis of coronary heart disease and susceptibility gene research of coronary heart disease are still required.
Disclosure of Invention
Aiming at the problems, the invention provides SNP loci related to coronary heart disease and application thereof, and mainly provides novel detection loci and novel detection reagents for coronary heart disease.
In order to solve the problems, the invention adopts the following technical scheme:
the application of IL5 gene rs2069812 locus or IL5 gene rs2057687 locus in preparing coronary heart disease screening and/or preventing and treating medicine. Coronary heart disease includes myocardial infarction and angina pectoris.
The application of the detection reagent of the IL5 gene rs2069812 locus and/or the IL5 gene rs2057687 locus in preparing coronary heart disease detection screening medicaments.
The IL5 gene sequence can be shown as SEQ ID NO.1, is a common sequence, does not influence the protection of detection sites related to the invention when single nucleotide of other sites of the IL5 gene is mutated, and is also in the scope of the invention when other sites are changed relative to SEQ ID NO. 1.
In some modes, the IL5 gene rs2069812 site detection reagent comprises a primer pair or a nucleic acid probe for amplifying the IL5 gene rs2069812 site, and/or the IL5 gene rs2057687 site detection reagent comprises a primer pair or a nucleic acid probe for amplifying the IL5 gene rs2057687 site.
In some modes, the amplified IL5 gene rs2069812 site comprises a primer pair of the following sequences
The sequence of the upstream primer CCTGCTGCTCATGAACAGAATA,
a downstream primer sequence AGTGACTCTTCCTTGACTCCA;
the amplified IL5 gene rs2057687 locus comprises a primer pair with the following sequence
The sequence of the upstream primer TTTTCCCATCAGCTCAGGGT,
downstream primer sequence ATAGTCCCAGTCTGCGTGTG.
The application of alleles obviously related to susceptibility of coronary heart disease in preparing coronary heart disease inspection screening and prevention and treatment medicines, wherein single nucleotide of the alleles at sites rs2069812 of IL5 gene and rs2057687 of IL5 gene are A, C respectively.
Application of low-risk alleles of coronary heart disease in preparing coronary heart disease inspection screening medicines, wherein single nucleotides of the alleles at positions rs2069812 of IL5 gene and rs2057687 of IL5 gene are G, T respectively.
The coronary heart disease inspection screening medicine comprises detection reagents of IL5 gene rs2069812 locus and/or IL5 gene rs2057687 locus.
Some modes, including a primer pair for amplifying the locus rs2069812 of the IL5 gene, and/or a primer pair for amplifying the locus rs2057687 of the IL5 gene;
preferably, the coronary heart disease detection screening drug is coronary heart disease susceptibility detection screening drug, at least comprising single nucleotide of IL5 gene rs2069812 site as A allele detection agent, single nucleotide of IL5 gene rs2057687 site as one of C allele detection agent, or
The coronary heart disease detection screening medicine is a coronary heart disease low risk detection screening medicine, and at least comprises a G allele detection agent which is a single nucleotide of an IL5 gene rs2069812 locus and one of T allele detection agents which is a single nucleotide of an IL5 gene rs2057687 locus.
In some modes, the amplified IL5 gene rs2069812 site comprises a primer pair of the following sequences
The sequence of the upstream primer CCTGCTGCTCATGAACAGAATA,
a downstream primer sequence AGTGACTCTTCCTTGACTCCA;
the amplified IL5 gene rs2057687 locus comprises a primer pair with the following sequence
The sequence of the upstream primer TTTTCCCATCAGCTCAGGGT,
downstream primer sequence ATAGTCCCAGTCTGCGTGTG.
PCR primer reagent for detecting susceptibility of coronary heart disease, the PCR primer reagent includes primer pair with the following sequence
The sequence of the upstream primer CCTGCTGCTCATGAACAGAATA,
a downstream primer sequence AGTGACTCTTCCTTGACTCCA;
and/or
The sequence of the upstream primer TTTTCCCATCAGCTCAGGGT,
downstream primer sequence ATAGTCCCAGTCTGCGTGTG.
A method of screening a biological sample for susceptibility to coronary heart disease:
extracting a nucleic acid sample from a biological sample to be detected;
specifically amplifying IL5 gene by using the extracted nucleic acid sample as a template, recovering and purifying an amplification product, and determining the nucleic acid sequence of the amplification product;
judging whether the single nucleotide at the rs2069812 locus of the determined nucleic acid sequence is A, if so, determining that the biological sample to be detected is a biological sample susceptible to coronary heart disease, and/or
Judging whether the single nucleotide at the rs2057687 locus of the determined nucleic acid sequence is C, if so, determining that the biological sample to be detected is a biological sample susceptible to coronary heart disease.
The application of the gene fragment in preparing the medicine for preventing and treating coronary heart disease is that the gene fragment is a gene fragment containing rs2069812 locus mononucleotide as G in the IL5 gene or a gene fragment containing rs2057687 locus mononucleotide as T in the IL5 gene. The gene segment is replaced to realize the aim of subsequent treatment or relapse prevention and the like.
A medicine for preventing and treating coronary heart disease comprises a gene vector containing
A gene fragment capable of replacing single nucleotide A at rs2069812 site in IL5 gene with single nucleotide G and expressing, or
A gene segment which can replace single nucleotide C at an rs2057687 site in the IL5 gene with single nucleotide T and express the single nucleotide T;
some manifestations of gene vectors are plasmids, adenoviral vectors. On the premise of not violating scientific ethics and related legal regulations, the existing or subsequent means for achieving the above purpose are all within the scope of the invention, and the requirement is that the gene fragment or the similar can be carried and replaced, and the specific model of the gene vector is not particularly limited.
The beneficial effects of the invention are as follows:
a new coronary heart disease detection site is found, and different risk grades are found for different alleles at the same time, so that a new scheme is provided for the diagnosis, prevention and treatment of the subsequent coronary heart disease.
Drawings
FIG. 1 is a diagram of a PCR amplification program;
FIG. 2 is a graph of rs2069812 typing results;
fig. 3 is a graph of rs2057687 typing results.
Detailed Description
The invention is further described below:
the application of the IL5 gene rs2069812 locus or the IL5 gene rs2057687 locus in preparing medicaments for screening and/or preventing coronary heart disease.
The application of the detection reagent of the IL5 gene rs2069812 locus and/or the IL5 gene rs2057687 locus in preparing coronary heart disease detection screening medicaments.
In some cases of high-association detection of coronary heart disease, single nucleotides of the alleles at positions rs2069812 and rs2057687 of the IL5 gene are A, C respectively; in low risk screening, the mononucleotides were G, T, respectively.
The foregoing embodiments may be described in some detail with reference to the following description, but are not specifically described, i.e., using existing or later-emerging equivalent techniques are within the scope of the invention. When the gene fragment is used as a prevention and treatment drug, the gene fragment can be used as a treatment target point and the like in the preparation process of the drug, or the related gene fragment containing the sites can be used as auxiliary reagents in the preparation process of the coronary heart disease prevention and treatment drug, such as testing, extraction and the like in the preparation process of biological drugs.
In some aspects, the IL5 gene rs2069812 site detection reagent comprises a primer pair that amplifies an IL5 gene rs2069812 site, and/or the IL5 gene rs2057687 site detection reagent comprises a primer pair that amplifies an IL5 gene rs2057687 site.
In some aspects, the primer pair for amplifying the rs2069812 site of the IL5 gene comprises an upstream primer 5'-CCTGCTGCTCATGAACAGAATA-3',
a downstream primer 5'-AGTGACTCTTCCTTGACTCCA-3';
the primer pair for amplifying the IL5 gene rs2057687 locus comprises
The primer set 5'-TTTTCCCATCAGCTCAGGGT-3' to be used in the upstream,
a downstream primer 5'-ATAGTCCCAGTCTGCGTGTG-3'.
The application of the alleles related to coronary heart disease susceptibility in preparing coronary heart disease inspection screening and prevention and treatment medicines is characterized in that the single nucleotides of the alleles at the locus rs2069812 of the IL5 gene and the locus rs2057687 of the IL5 gene are A, C respectively. In the preparation of the prevention and treatment medicine, the preparation is mainly used as an action target point in the research and development and preparation process of the medicine.
The application of the low-risk alleles of the coronary heart disease in preparing coronary heart disease examination screening medicaments is characterized in that the single nucleotides of the alleles at the locus rs2069812 of the IL5 gene and the locus rs2057687 of the IL5 gene are G, T respectively. However, the alleles have a certain reference significance for coronary heart disease detection.
The coronary heart disease inspection screening medicine comprises detection reagents of IL5 gene rs2069812 locus and/or IL5 gene rs2057687 locus.
In some embodiments, the primer pair or nucleic acid probe comprises a primer pair or nucleic acid probe for amplifying the locus rs2069812 of the IL5 gene, and/or a primer pair or nucleic acid probe for amplifying the locus rs2057687 of the IL5 gene;
the nucleic acid probe may be a similar gene detection probe in one mode, and is not particularly limited as long as it is possible.
Preferably, the coronary heart disease examination and screening drug is coronary heart disease susceptibility (susceptibility means susceptibility to coronary heart disease, with medium and high risk, risk assessment criteria may refer to other detection means in some ways), at least comprises a single nucleotide at the locus rs2069812 of the IL5 gene as an A allele detection agent, a single nucleotide at the locus rs2057687 of the IL5 gene as one of the C allele detection agents, or
The coronary heart disease detection screening medicine is a coronary heart disease low risk detection screening medicine, and at least comprises a G allele detection agent which is a single nucleotide of an IL5 gene rs2069812 locus and one of T allele detection agents which is a single nucleotide of an IL5 gene rs2057687 locus.
In some aspects, the primer pair for amplifying the rs2069812 site of the IL5 gene comprises an upstream primer 5'-CCTGCTGCTCATGAACAGAATA-3',
a downstream primer 5'-AGTGACTCTTCCTTGACTCCA-3';
the primer pair for amplifying the IL5 gene rs2057687 locus comprises
The primer set 5'-TTTTCCCATCAGCTCAGGGT-3' to be used in the upstream,
a downstream primer 5'-ATAGTCCCAGTCTGCGTGTG-3'.
PCR primer for detecting susceptibility of coronary heart disease, said PCR primer at least includes one of the following
In some embodiments with better detection effect, the single nucleotide of the locus rs2069812 of the allele IL5 gene and the locus rs2057687 of the IL5 gene related to the detection of the primer and the probe is A, C respectively.
A method of screening a biological sample for susceptibility to coronary heart disease:
extracting a nucleic acid sample from a biological sample to be detected;
specifically amplifying IL5 gene by using the extracted nucleic acid sample as a template, recovering and purifying an amplification product, and determining the nucleic acid sequence of the amplification product;
judging whether the single nucleotide at the rs2069812 locus of the determined nucleic acid sequence is A, if so, determining that the biological sample to be detected is a biological sample susceptible to coronary heart disease, and/or
Judging whether the single nucleotide at the rs2057687 locus of the determined nucleic acid sequence is C, if so, determining that the biological sample to be detected is a biological sample susceptible to coronary heart disease.
The application of the gene fragment in preparing the medicine for preventing and treating coronary heart disease is that the gene fragment is a gene fragment containing rs2069812 site mononucleotide as G in IL5 gene or a gene fragment containing rs2057687 site mononucleotide as T in IL5 gene.
A medicine for preventing and treating coronary heart disease comprises a gene vector containing
An IL5 gene rs2069812 locus mononucleotide G gene fragment (comprising an allele fragment) and can replace a corresponding locus mononucleotide A gene fragment of the IL5 gene rs2069812 locus and express (the core purpose is to replace mononucleotide A with mononucleotide G); or, an IL5 gene rs2057687 locus mononucleotide T gene fragment (comprising an allele fragment) and can replace a corresponding locus IL5 gene rs2057687 locus mononucleotide C gene fragment and express (the core purpose is to replace mononucleotide C with mononucleotide T); some manifestations of gene vectors are plasmids, adenoviral vectors. Such as transcription activator-like effector nucleases, are well proven techniques. The gene vector can introduce any one of the two gene segments into human body substitution defect IL5 gene rs2069812 locus mononucleotide A or IL5 gene rs2057687 locus mononucleotide C, thereby reducing the risk of coronary heart disease of human body and even treating coronary heart disease. The mutant gene is replaced to restore the normal gene sequence to realize treatment, thereby achieving the aim of prevention and treatment. Presently, genetic vectors are preferably considered to be known and mature, but are not intended to exclude other vectors having similar functions, although it is within the scope of the invention that future innovations will be recognized.
The following is a detailed description in connection with some specific experiments:
1. human peripheral blood whole genome DNA extraction
Human peripheral blood whole genome DNA was extracted using the BloodGen Mini Kit blood gene column type small extraction kit (CW 2087) provided for century. The operation steps are according to the instruction of the kit.
2. Primer design
After inputting a gene IL5 in Ensemble, obtaining all gene sequences, displaying all mutation sites, finding the positions of all SNP, designing primers by using Primer and Genetol software, and performing electronic PCR on UCSC websites after the primers are obtained, wherein the PCR result shows that no special structure exists and the PCR target band is single, thus the synthetic primers can be customized. The primers used in the study were prepared by synthesis from Tianyi Huiyuan corporation, and each primer was split into two tubes in an amount of 4 OD.
IL5 gene locus information is shown in the following table:
genotyping primers designed for SNPs are shown in the following table:
PCR amplification
The amplification system and procedure were as follows:
amplification system (25 μl):
the PCR amplification method of coronary heart disease susceptibility gene includes the following steps
And (3) constructing an amplification system: mixing an upstream primer, a downstream primer, DNA to be detected, taq DNA polymerase and nucleic acid dye,
DNA denaturation: under the thermal action of double-stranded DNA at 90-96 deg.C, the hydrogen bond is broken to form single-stranded DNA,
annealing: in the optimum Tm environment of SNP, the primer binds to the DNA template to form a partial double strand,
extension: under the action of Taq DNA polymerase at 70-72 deg.C, dNTP is used as raw material to extend from 5 '-end to 3' -end to synthesize template complementary DNA strand,
the DNA is denatured, annealed and extended for several times, and finally the temperature is recovered.
The amplification procedure is shown in FIG. 1. Wherein, the optimal Tm of rs2069812 is 55 ℃, and the optimal Tm of rs2057687 is 58 ℃.
SNP typing
The high-resolution melting curve is a new real-time quantitative technology developed on the basis of real-time fluorescence PCR, and gene mutation scanning and genotyping are performed by monitoring the combination condition of double-stranded DNA fluorescent dye and PCR amplification product in the heating process in real time. If SNP loci exist in the double-stranded DNA fragments, the SNP loci are melted successively due to different single bases in the heating process, so that whether SNP exists in the DNA fragments can be judged according to the melting curve and the melting temperature. Since different SNP loci and genotypes can generate different melting curve peak shapes, the different SNP loci and genotypes can be effectively distinguished according to the melting curve. The wild type, heterozygous mutation, pure mutation and mutation can be accurately distinguished according to the curve of the detection sample and the curve of the positive control sample, and the rapid typing can be carried out by corresponding software. 36 PCR amplified products (3 genotype samples containing 3 SNPs as positive control samples) were placed on a Rotor-Gene 6000 fluorescent quantitative PCR apparatus for typing detection, and the results were read. The nucleic acid dye used in this experiment was SYTO 9 fluorescent dye and the HRM instrument used was Rotor-Gene 6000. By using the method, the typing result of the samples can be obtained rapidly and accurately, and 36 samples can be detected every 8 minutes on average. The result of the method is verified by Sanger sequencing, and all positive samples are correctly detected with 100% accuracy. Fig. 2 shows the typing result of rs2069812, and fig. 3 shows the typing result of rs 2057687.
Description of the preferred embodiments
Two newly discovered SNP sites on IL5 gene are related to susceptibility of coronary heart disease (case-control analysis): the study selects 1863 Chinese Han coronary heart disease crowd samples, 1920 healthy control crowd samples, collects clinical data and peripheral blood samples, and extracts whole genome DNA by using a blood gene column type small extraction Kit provided by Kangjia BloodGenMini Kit.
SNP loci rs2057687 and rs2069812 of the above case and control populations were genotyped. After each sample genotype was obtained, the two SNPs were first subjected to hadi-weinberg equilibrium detection.
The specific analysis is as follows: if p represents the frequency of gene A alleles; q represents the frequency of the allele of the gene a, the frequency of genotype AA is p2, the frequency of genotype AA is 2pq, and the frequency of genotype AA is q2. The sum of genotype frequencies is equal to 1, i.e. p2+2pq+q2=1. In case and control association analysis studies, the detected variation requires a Hardy-Wenberg equilibrium test in the control population, and the variation from this test indicates that the variation is not biased in the population under study and is representative of the genetic characteristics of the entire population.
The sites meeting the Hardy-Wenberg equilibrium were further subjected to association analysis using chi-square to examine whether the alleles of each SNP site correlated with the case-control group, specifically: chi-square test is a common hypothesis test method based on χ2 distribution, and its null hypothesis H0 means that the observed frequency is not different from the expected frequency. The basic idea of this test is: first, on the assumption that H0 is established, a χ2 value, which is the degree of deviation between the observed frequency and the theoretical frequency, is calculated. The probability P value for the current statistic or more extreme case is then determined from the χ2 distribution and the degrees of freedom where the H0 assumption holds. If the P value is small, the degree of deviation between the observed frequency and the theoretical frequency is large, and the H0 assumption should be refused, namely, the studied data are considered to have obvious differences; otherwise the H0 hypothesis cannot be rejected, i.e. the difference between the investigated samples cannot be considered. The study was tested using a 2 x 2 list chi-square when comparing differences in the distribution of smoking rate, male and female rate, hypertension rate, and diabetes rate in clinical data of case group and control group. In the correlation analysis of SNP loci and coronary heart disease, a 2X 2 list chi-square is used for checking whether the SNP allele distribution has a significant difference in the case group and the control group. Logistic regression is commonly used in case-control association analysis studies to assess independent relationships between genotype and disease. Our dependent variables in this study were disease states, divided into two categories, coronary heart disease and non-coronary heart disease, independent variables contained 10 independent risk factors for SNP genotype and coronary heart disease: sex, age, hypertension, diabetes, smoking, BMI and four blood lipids. And 10 risk factors are taken as covariates in Logistic regression calculation, genotypes of SNP are taken as independent variables, and P values and OR values and corresponding 95% placement intervals of the independent variables and diseases are obtained after SPSS calculation. When the calculated P value of the genotype is smaller than 0.05, the genotype is obviously related to the disease independently, and has statistical significance, and when the calculated P value is larger than 0.05, the genotype is not related to the disease.
The results are shown in the following table.
Table 1: allele-related analysis results of SNP and CAD on IL5
Note that: through analysis, the genotype frequencies of the two SNPs meet the genetic Hadi-Wenberg equilibrium (P > 0.05) in the total population, and the study subjects are considered to have good representativeness. OR (95% ci) represents the odds ratio (95% confidence interval), for disease incidence, the OR value of the different genotypes is the estimated value of the relative risk of the gene for disease occurrence, when OR value=1, it indicates that the factor is not contributing to disease occurrence, when OR value is greater than 1, it indicates that the factor is a risk factor, when OR value is less than 1, it indicates that the factor is a protection factor; the P value represents statistical significance, and when P < 0.05 represents a significant difference between the compared samples, pobs represents P value of common risk factors not correcting coronary heart disease, padj represents P value after correcting common risk factors of coronary heart disease including gender, age, hypertension, diabetes, smoking, blood lipid, etc.
The results in Table 1 show that the difference between the allele C and the allele T at the SNP locus rs2057687 in the case and the control group is remarkable (P < 0.05 after correction), which indicates that the allele C and the allele T at the SNP locus rs2057687 are related to susceptibility to coronary heart disease, the number of people with the allele C in the coronary heart disease crowd is obviously higher than that in the control group, namely, the allele C at the SNP locus rs2057687 is judged to be susceptibility allele of coronary heart disease, and the allele T is low risk allele of coronary heart disease.
Similarly, the difference between the case and the control group between the allele G and A at the SNP locus rs2069812 is remarkable (P < 0.05 after correction), which indicates that the allele G and A at the SNP locus rs2069812 are related to susceptibility to coronary heart disease, and the number of people with A at the allele in the population of coronary heart disease is obviously higher than that in the control group, namely, the allele A at the SNP locus rs2069812 is judged to be susceptibility allele of coronary heart disease, and the allele G is low risk allele of coronary heart disease.
It will be apparent to those skilled in the art that various modifications to the above embodiments may be made without departing from the general spirit and concepts of the invention. Which fall within the scope of the present invention. The protection scheme of the invention is subject to the appended claims.
Sequence listing
<110> affiliated synergetic Hospital of the university of science and technology, shangji medical college
<120> SNP locus related to coronary heart disease and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 2
<211> 2078
<212> DNA
<213> person (Huma)
<400> 2
atgcactttc tttgccaaag gcaaacgcag aacgtttcag agccatgagg atgcttctgc 60
atttgagttt gctagctctt ggagctgcct acgtgtatgc catccccaca gaaattccca 120
caagtgcatt ggtgaaagag accttggcac tgctttctac tcatcgaact ctgctgatag 180
ccaatgaggt aattttcttt atgattccta cagtctgtaa agtgcatagg taatcatttg 240
tgatggttcc tttactatat atagagatct gttataaata ataagattct gagcacatta 300
gtacatgggt gataactaca tcaccagcaa acattctgtt aaaagttatg aatgctggtg 360
tgctgtaaaa atgattgtat ttcctttcct ctccagactc tgaggattcc tgttcctgta 420
cataaaaatg taagttaaat tatgattcag taaaatgatg gcatgaataa gtaaatttcc 480
tgttttaagc tgtaaatcat tagttatcat tggaactatt taattttcta tattttgttt 540
tcatatgggt ggctgtgaat gtctgtactt ataaatatga ggaatgactt tttatcaagt 600
agaatccttt aaacaagtgg attaggctct ttggtgatgt tgttagtttg cctcccaaag 660
agcatcgtgt cagggattct ttccagaagg attccacact gagtgagagg tgcgtgctag 720
tctccgtgca gttctgactc tttctcactc taacgtgttt ctgaaagtat tagcaactca 780
gaattatatt tttagaacca tgatcagtag acattaaaat atataacaaa tgccctatat 840
taataatttc tgcatactta aataattatg actatatgat ggtgttgtat gcatttgaat 900
atgtcctggt catattaaaa tgtaaaatat atagttttat tagtctaaat agaataaaac 960
taccagctag aactgtagaa acacattgat atgagtttaa tgtataatgc attacacttc 1020
caaaacattt ttttccagtt acataattaa gttatatcct ttataaaact cctcagtaat 1080
catataagct tcatctactt tttgaaaatt ttatcttaat atgtggtggt ttgttgccta 1140
gaaaacaaac aaaaaactct ttggagaagg gaactcatgt aaataccaca aaacaaagcc 1200
taactttgtg gaccaaaatt gttttaataa ttatttttta attgatgaat taaaaagtat 1260
atatatttat tgtgtacaat atgatgtttt gaagtatgta tacattgcag aatggacaat 1320
ggaccaaatt tttatacctt gtcttgatta tttgcatttt aaaaattttc ctcatttagc 1380
accaactgtg cactgaagaa atctttcagg gaataggcac actggagagt caaactgtgc 1440
aagggggtac tgtggaaaga ctattcaaaa acttgtcctt aataaagaaa tacattgacg 1500
gccaaaaagt aagttacaca cattcaatgg aagctatatt tgtctggctg tgcctatttc 1560
tatggaattg acagtttcct gtaataccta ttgtcatttt tcttttttca cagaaaaagt 1620
gtggagaaga aagacggaga gtaaaccaat tcctagacta cctgcaagag tttcttggtg 1680
taatgaacac cgagtggata atagaaagtt gagactaaac tggtttgttg cagccaaaga 1740
ttttggagga gaaggacatt ttactgcagt gagaatgagg gccaagaaag agtcaggcct 1800
taattttcag tataatttaa cttcagaggg aaagtaaata tttcaggcat actgacactt 1860
tgccagaaag cataaaattc ttaaaatata tttcagatat cagaatcatt gaagtatttt 1920
cctccaggca aaattgatat acttttttct tatttaactt aacattctgt aaaatgtctg 1980
ttaacttaat agtatttatg aaatggttaa gaatttggta aattagtatt tatttaatgt 2040
tatgttgtgt tctaataaaa caaaaataga caactgtt 2078
Claims (2)
1. Application of a reagent for detecting IL5 gene rs2069812 locus in preparing a preparation for screening coronary heart disease risk; wherein, the liquid crystal display device comprises a liquid crystal display device,
when the mononucleotide of the locus rs2069812 of the IL5 gene is A, the preparation for screening coronary heart disease risk is a coronary heart disease susceptibility screening preparation,
when the mononucleotide of the locus rs2069812 of the IL5 gene is G, the coronary heart disease risk screening preparation is a coronary heart disease low risk screening preparation.
2. The use according to claim 1, wherein the detection reagent when the locus rs2069812 of the IL5 gene is G is a primer pair
Upstream primer sequence: CCTGCTGCTCATGAACAGAATA the number of the individual pieces of the plastic,
downstream primer sequence: AGTGACTCTTCCTTGACTCCA;
detection reagent with IL5 gene rs2069812 site as A as primer pair
Upstream primer sequence: CCTGCTGCTCATGAACAGAATA the number of the individual pieces of the plastic,
downstream primer sequence: AGTGACTCTTCCTTGACTCCA.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310631295.1A CN117757914A (en) | 2021-08-08 | 2021-08-08 | SNP locus related to coronary heart disease in IL5 gene and application thereof |
| CN202110905130.XA CN113637738B (en) | 2021-08-08 | 2021-08-08 | SNP locus related to coronary heart disease and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110905130.XA CN113637738B (en) | 2021-08-08 | 2021-08-08 | SNP locus related to coronary heart disease and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310631295.1A Division CN117757914A (en) | 2021-08-08 | 2021-08-08 | SNP locus related to coronary heart disease in IL5 gene and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113637738A CN113637738A (en) | 2021-11-12 |
| CN113637738B true CN113637738B (en) | 2023-07-28 |
Family
ID=78419978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110905130.XA Active CN113637738B (en) | 2021-08-08 | 2021-08-08 | SNP locus related to coronary heart disease and application thereof |
| CN202310631295.1A Pending CN117757914A (en) | 2021-08-08 | 2021-08-08 | SNP locus related to coronary heart disease in IL5 gene and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310631295.1A Pending CN117757914A (en) | 2021-08-08 | 2021-08-08 | SNP locus related to coronary heart disease in IL5 gene and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN113637738B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102108396A (en) * | 2009-12-29 | 2011-06-29 | 何青 | Coronary artery disease (CAD) and acute myocardial infarction (AMI) susceptibility diagnosis kit and use of single nucleotide polymorphism (SNP) in preparation thereof |
| WO2013078690A1 (en) * | 2011-12-03 | 2013-06-06 | Gu Jieruo | Ankylosing spondylitis susceptibility and mononucleotide polymorphism detection method, kit and use thereof |
| CN104651354A (en) * | 2015-01-21 | 2015-05-27 | 田小利 | SCML4 gene sequence and expression change detection and application of SCML4 gene sequence in coronary heart disease prediction |
| CN112342292A (en) * | 2020-11-23 | 2021-02-09 | 新疆医科大学第一附属医院 | Reagent for in vitro detection of SelS gene promoter mutation and application of reagent in preparation of coronary heart disease screening kit |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI118265B (en) * | 2004-01-15 | 2007-09-14 | Jurilab Ltd Oy | A method for detecting the risk of acute myocardial infarction and coronary heart disease |
| JP2009521905A (en) * | 2004-03-05 | 2009-06-11 | アプレラ コーポレイション | Genetic polymorphism associated with coronary heart disease, detection method and use thereof |
-
2021
- 2021-08-08 CN CN202110905130.XA patent/CN113637738B/en active Active
- 2021-08-08 CN CN202310631295.1A patent/CN117757914A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102108396A (en) * | 2009-12-29 | 2011-06-29 | 何青 | Coronary artery disease (CAD) and acute myocardial infarction (AMI) susceptibility diagnosis kit and use of single nucleotide polymorphism (SNP) in preparation thereof |
| WO2013078690A1 (en) * | 2011-12-03 | 2013-06-06 | Gu Jieruo | Ankylosing spondylitis susceptibility and mononucleotide polymorphism detection method, kit and use thereof |
| CN104651354A (en) * | 2015-01-21 | 2015-05-27 | 田小利 | SCML4 gene sequence and expression change detection and application of SCML4 gene sequence in coronary heart disease prediction |
| CN112342292A (en) * | 2020-11-23 | 2021-02-09 | 新疆医科大学第一附属医院 | Reagent for in vitro detection of SelS gene promoter mutation and application of reagent in preparation of coronary heart disease screening kit |
Non-Patent Citations (5)
| Title |
|---|
| Genetic Analysis Reveals Different Mechanisms of IL-5 Involved in the Development of CAD in a Chinese Han Population;Wenjuan Zhang等;Oxidative Medicine and Cellular Longevity;1-10 * |
| PON基因簇潜在功能多态位点与冠心病的关联研究;王晓玲,范中杰,黄建凤,宿少勇,赵建功,顾东风;遗传学报(07);11-17 * |
| Th1 和Th2 相关白介素基因多态性与 Graves 病的相关性研究;朱巍等;内科理论与实践;第8卷(第4期);229-233 * |
| 冠心病患者血浆IL210 , IL217 , IL218 和C 反应蛋白的水平检测;石胜伟等;临床心血管病杂志;第24卷(第10期);755-758 * |
| 细胞色素氧化酶基因CYP1A2 多态性与新疆汉族 和维吾尔族人群冠心病的相关性;邹金国等;临床研究;第31卷(第4期);422-427 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117757914A (en) | 2024-03-26 |
| CN113637738A (en) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8906620B2 (en) | Exon grouping analysis | |
| CN107488711B (en) | Method for detecting genotype of point mutation and kit thereof | |
| JP6343404B2 (en) | Gene mutation detection method | |
| CN110846408A (en) | Primer combination for detecting TTN gene mutation and application thereof | |
| CN109182493A (en) | The primer and kit and its detection method of people's 16p11.2 microdeletion syndrome detection | |
| CN109837330A (en) | A kind of probe and method detecting TREM2 gene pleiomorphism | |
| CN113637738B (en) | SNP locus related to coronary heart disease and application thereof | |
| CN115948532A (en) | SMA detection kit based on digital PCR technology | |
| CN104073548A (en) | Mononucleotide polymorphism detection method based on melting curves and kit thereof | |
| KR101992952B1 (en) | Composition, kit for predicting the risk of developing cardiovascular disease related to Cholesterol efflux capacity, and method using the same | |
| KR20100083487A (en) | Composition for diagnosis of wilson's disease | |
| JP2006254735A (en) | Diabetic disease-sensitive gene, and method for detecting difficulty or easiness of being infected with diabetes | |
| CN111041086B (en) | SNP site susceptible to RPL13 gene congenital heart disease and application thereof | |
| KR101167945B1 (en) | Polynucleotides derived from ATG16L1 gene comprising single nucleotide polymorphisms, microarrays and diagnostic kits comprising the same, and analytic methods for autism spectrum disorders using the same | |
| JP2005192418A (en) | Simple method for detecting specific sequence to be detected | |
| CN109097464B (en) | Application of SNP (single nucleotide polymorphism) site of CFAP43 gene | |
| JP2006254739A (en) | Diabetic disease-sensitive gene, and method for detecting difficulty or easiness of being infected with diabetes | |
| US20040126800A1 (en) | Regulatory single nucleotide polymorphisms and methods therefor | |
| US20070264648A1 (en) | Dna Oligomer, Genetic Marker and Dna Oligomer Set for Prediction of Onset of Side-Effect from Radiation Therapy, and Method for Predicting Onset of Side-Effect | |
| Marian | Molecular approaches for screening of genetic diseases | |
| CN118048449A (en) | Method for detecting single nucleotide polymorphism of CREG1 gene by utilizing Forced-PCR-RFLP and application thereof | |
| CN111593117A (en) | Application of CRYBB3 gene mutation as Marfan syndrome diagnosis marker | |
| KR101196239B1 (en) | Diagnostic kit for premature ovarian failure comprising polynucleotides having single nucleotide polymorphism derived from TG gene and analytic method using the same | |
| KR101071081B1 (en) | Polynucleotides comprising single nucleotide polymorphism derived from DEFA4 gene, microarrays and diagnostic kits comprising the same, and detection methods using the same | |
| KR20160083758A (en) | Detection of mutations in ATP7B gene using PCR-LDR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |